You should not take Megace ES if you are hypersensitive to megestrol acetate or any component of the formulation. Do not take Megace ES if you are pregnant, suspect that you are pregnant, or are nursing. If you become pregnant while taking this medication, tell your healthcare provider immediately. Women who may become pregnant should be certain to use contraception while taking Megace ES.
Reports on new onset diabetes, worsening of pre-existing diabetes, overt Cushing's Syndrome (which may be characterized by weight gain in the midsection or upper back, rounding of the face, weakness, fatigue, high blood pressure and bruising), and adrenal insufficiency (which may be characterized by low blood pressure, upset stomach, vomiting, dizziness, or weakness) have been associated with chronic use of megestrol acetate.
Be sure to tell your healthcare provider if you experience any side effects while taking Megace ES.
Strativa Pharmaceuticals is the proprietary products division of Par Pharmaceutical, Inc. Supported by Par's financial and organizational capabilities including substantial cash resources, Strativa Pharmaceuticals is committed to developing and marketing novel prescription drugs. Its initial focus is on supportive care therapeutics in HIV and oncology. Drawing on the specialty products expertise of its staff, Strativa possesses the resources to prepare products for introduction and to help ensure their success after launch. For additional information, please visit http://www.strativapharma.com
Par Pharmaceutical, Inc. develops, manufactures and markets generic
drugs and innovative branded pharmaceuticals for specialty markets. For
press release a
|SOURCE Strativa Pharmaceuticals|
Copyright©2007 PR Newswire.
All rights reserved